OLMESARTAN +AMLOIPINE TREATMENT IN DIABETIC PATIENTS: EVALUATING BLOOD PRESSURE CONTROL AFTER 48 HOURS FROM THE LAST ADMINISTRATION (MISSED DOSE).

Trial Profile

OLMESARTAN +AMLOIPINE TREATMENT IN DIABETIC PATIENTS: EVALUATING BLOOD PRESSURE CONTROL AFTER 48 HOURS FROM THE LAST ADMINISTRATION (MISSED DOSE).

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2016

At a glance

  • Drugs Olmesartan medoxomil/amlodipine (Primary) ; Perindopril/amlodipine
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms OLMAML
  • Sponsors Menarini
  • Most Recent Events

    • 24 May 2016 Results (post hoc analysis of a substudy) comparing effect of olmesartan/amlodipine versus perindopril/amlodipine published in the American Journal of Hypertension.
    • 15 Jun 2015 Primary endpoint Office diastolic blood pressure has been met as per results presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.
    • 15 Jun 2015 Results presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top